Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Coal Tar→

Coal Tar Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8007-45-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Topical coal tar preparationkeratoplastic and anti-inflammatory dermatological agent
Mechanism of action
The mixture of polycyclic aromatic hydrocarbons and other coal-tar constituents reduces epidermal proliferation and has antipruritic and anti-inflammatory effects. The precise active constituents and mechanism vary with formulation.
Indications / reported uses
  • Topical treatment of psoriasis and seborrhoeic dermatitis in authorised scalp and skin preparations; use concentration, exposure time and treated area according to product information

Sources: NHS — Coal tar · NLM MeSH — Coal tar · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Coal Tar Environmental Risk Assessment (ERA) (the Coal Tar ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.